Gilead Sciences, Inc.'s (NASDAQ:GILD) stock price has fallen 4% over the past two months, which I estimate is mainly due to continued apathy and fear on Wall Street even after progress in tariff ...

At ASCO, Gilead’s cell therapy unit Kite Pharma reported some early positive data for its anti-CD19/CD20 bicistronic CAR-T therapy in advanced B-cell lymphoma. Another bivalent CAR-T candidate ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant have gained 21.1% year to date against the industry’s decline of 4.7 ...

Gilead previously said the Phase 3 study in 443 patients with advanced triple-negative breast cancer whose tumors express PD-L1 - the protein targeted by drugs like Keytruda - had met its goal.

May 30 (Reuters) - Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding ...

Goodbye to Gilead. Posted: June 1, 2025 | Last updated: June 1, 2025 "The Handmaid's Tale" comes to an end after six seasons on Hulu. One of the stars, O-T Fagbenle, talks about his character and ...

Gilead Sciences. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company ...

Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump ...

Gilead is expected to post earnings of $1.99 per share for the current quarter, representing a year-over-year change of -1%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.1%.

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical powerhouse known for its innovative HIV treatments, is navigating a complex landscape of opportunities and challenges as it seeks to ...

Following the Ascent-04 win in PD-L1-positive disease, Gilead last week said the Ascent-03 trial comparing Trodelvy with chemo in first-line PD-L1-negative TNBC also demonstrated a “highly ...